Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David A Largaespada

Showing results (21-30 of 206) with videos related to

Pageof 21
Sort By:
Trends in Genetics : TIG|September 11, 2017
Transposons As Tools for Functional Genomics in Vertebrate ModelsKoichi Kawakami, David A Largaespada, Zoltán Ivics
Journal of Hepatology|March 20, 2012
Why men are at higher risk for hepatocellular carcinoma?Vincent W Keng, David A Largaespada, Augusto Villanueva
Methods in Molecular Biology (Clifton, N.J.)|December 14, 2018
CRISPR/Cas9-Based Positive Screens for Cancer-Related TraitsNicholas J Slipek, Jyotika Varshney, David A Largaespada
International Journal of Molecular Sciences|March 6, 2021
Spontaneous and Engineered Large Animal Models of Neurofibromatosis Type 1Sara H Osum, Adrienne L Watson, David A Largaespada
Oncotarget|November 19, 2015
Coping with cancer genes altered by copy numberNatalie K Wolf, David A Largaespada, Branden S Moriarity
Current Gene Therapy|February 7, 2006
Nonviral vectors for cancer gene therapy: prospects for integrating vectors and combination therapiesJohn R Ohlfest, Andrew B Freese, David A Largaespada
Nucleic Acids Research|January 10, 2003
MTID: a database of Sleeping Beauty transposon insertions in miceKevin Roberg-Perez, Corey M Carlson, David A Largaespada
Oncoimmunology|November 20, 2013
Alkylating chemotherapy may exert a uniquely deleterious effect upon neo-antigen-targeting anticancer vaccinationAdam J Litterman, Arkadiusz Z Dudek, David A Largaespada
Seminars in Cell & Developmental Biology|January 29, 2014
Mouse models of cancer: Sleeping Beauty transposons for insertional mutagenesis screens and reverse genetic studiesBarbara R Tschida, David A Largaespada, Vincent W Keng
Experimental Hematology|June 15, 2007
Vav promoter-tTA conditional transgene expression system for hematopoietic cells drives high level expression in developing B and T cellsWon-Il Kim, Stephen M Wiesner, David A Largaespada
Pageof 21

Showing results (21-30 of 206) with videos related to

Sort By:
Pageof 21
Trends in Genetics : TIG|September 11, 2017
Transposons As Tools for Functional Genomics in Vertebrate ModelsKoichi Kawakami, David A Largaespada, Zoltán Ivics
Journal of Hepatology|March 20, 2012
Why men are at higher risk for hepatocellular carcinoma?Vincent W Keng, David A Largaespada, Augusto Villanueva
Methods in Molecular Biology (Clifton, N.J.)|December 14, 2018
CRISPR/Cas9-Based Positive Screens for Cancer-Related TraitsNicholas J Slipek, Jyotika Varshney, David A Largaespada
International Journal of Molecular Sciences|March 6, 2021
Spontaneous and Engineered Large Animal Models of Neurofibromatosis Type 1Sara H Osum, Adrienne L Watson, David A Largaespada
Oncotarget|November 19, 2015
Coping with cancer genes altered by copy numberNatalie K Wolf, David A Largaespada, Branden S Moriarity
Current Gene Therapy|February 7, 2006
Nonviral vectors for cancer gene therapy: prospects for integrating vectors and combination therapiesJohn R Ohlfest, Andrew B Freese, David A Largaespada
Nucleic Acids Research|January 10, 2003
MTID: a database of Sleeping Beauty transposon insertions in miceKevin Roberg-Perez, Corey M Carlson, David A Largaespada
Oncoimmunology|November 20, 2013
Alkylating chemotherapy may exert a uniquely deleterious effect upon neo-antigen-targeting anticancer vaccinationAdam J Litterman, Arkadiusz Z Dudek, David A Largaespada
Seminars in Cell & Developmental Biology|January 29, 2014
Mouse models of cancer: Sleeping Beauty transposons for insertional mutagenesis screens and reverse genetic studiesBarbara R Tschida, David A Largaespada, Vincent W Keng
Experimental Hematology|June 15, 2007
Vav promoter-tTA conditional transgene expression system for hematopoietic cells drives high level expression in developing B and T cellsWon-Il Kim, Stephen M Wiesner, David A Largaespada
Pageof 21